Table 1.

Demographic and baseline characteristics at admission

Characteristic		Study participants (N=220)
		n	%
Gender	Female	124	56
Age distribution (years)	12 to <18	42	19
	18 to <30	116	53
	≥30	62	28
Race	White	198	90
	Hispanic	12	5
	Unknown/Other	10	5
Genotype	Homozygous F508del	121	55
	Heterozygous F508del	82	37
	Other	16	7
	Not available	1	1
Insurance status*	Enrolled in Medicaid	76	37
Pancreatic status*	Prescribed pancreatic enzymes	196	89
FEV1 % predicted*	<40	74	36
	40–<70	84	41
	70–<100	42	21
	≥100	3	1
Respiratory microbiology*†‡	Pseudomonas aeruginosa	154	71
	Mucoid P. aeruginosa	121	56
	Staphylococcus aureus (methicillin susceptible)	78	36
	Methicillin-resistant S. aureus	84	39
	Stenotrophomonas maltophilia	31	14
	Achromobacter xylosoxidans	20	9
	Burkholderia cepacia complex	6	3
	Aspergillus spp.	47	22
Non-tuberculous Mycobacteria (NTM)*	Yes	16	7
Allergic bronchopulmonary aspergillosis (ABPA)*	Yes	28	13
CF-related diabetes mellitus*	Yes	86	39
Chronic CF medications*†‡	Inhaled tobramycin	155	71
	Inhaled aztreonam	111	51
	Inhaled colistimethate	30	14
	Dornase alfa	207	95
	Hypertonic saline	170	78
	Azithromycin	164	75
	Ivacaftor	8	4

^*Excludes missing data for insurance status (n = 14), pancreatic status (n = 1), FEV₁ % predicted (n = 17), respiratory microbiology (n = 4), non-tuberculous Mycobacteria (n = 2), ABPA (n = 1), CF-related diabetes mellitus (n = 1), chronic CF medications (n = 1)

^†Includes respiratory cultures recorded up to 6 months prior to admission and chronic medications recorded up to 12 months prior

^‡Categories are not mutually exclusive and may add up to >100%